This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at bakerdan@wsu.edu.
Mechanism of action:
Decreased chloride secretion and volume in the gastrointestinal tract through the inhibition of both the cyclic adenosine monophosphate (cAMP)-stimulated cystic fibrosis transmembrane conductance regulator (CFTR) chloride ion (Cl 2 ) channel and the calcium-activated Cl 2 channels at the luminal membrane of enterocytes. 
Analog of naturally occurring human glucagon-like peptide-2 (GLP-2), a peptide secreted by L-cells of the distal intestine. GLP-2 is known to increase intestinal and portal blood flow and inhibit gastric acid secretion. To decrease the risk of next-morning impairment, the dose of zolpidem is being reduced: Women: Decreased from 10 mg to 5 mg for immediate-release products and from 12.5 mg to 6.25 mg for extended-release products. Men: Recommendation for use of lower doses similar to those recommended for women. Middle-of-the night awakening products (eg, Intermezzo): no change in dose a Practitioners are encouraged to check the FDA's MEDWATCH Web site (http://www.fda.gov/medwatch/safety.htm) for updated information.
